Cite
MLA Citation
R Camidge et al.. “LBA1Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial.” Annals of oncology, vol. 30, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100098040231.0x000036